Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Chengdu Baiyu Pharmaceutical Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio is currently handled by 1 distinct examiner and art unit. William Y. Lee is the busiest examiner, overseeing the pending office action.
The prosecution for Chengdu Baiyu Pharmaceutical Co. Ltd. is centralized, with the 1 pending office action assigned to a single examiner. This indicates that the company's current efforts in biotechnology are focused on the review process within the distinct art unit under William Y. Lee.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17601148 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME | LEE, WILLIAM Y | 12d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17601148 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME | LEE, WILLIAM Y | 1623 | §103 | Final Rejection | 12d | Pending | Oct 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial